Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Clopidogrel prices in Germany, the highest-cost reporting region, rose 8.0% in H1 2026, climbing from USD 79.1/KG in Q1 to USD 85.4/KG by Q2 as spring cardiovascular secondary prevention, acute coronary syndrome, and coronary stent dual antiplatelet therapy procurement and firmer thienopyridine synthesis intermediate costs drove consistent buying following the brief Q1 2026 pricing moderation. Globally, the average rose from USD 54.98/KG in Q1 to USD 59.40/KG in Q2, an 8.0% gain. For H2 2026, a global average of USD 58.0-65.1/KG is expected, with continued firming on Middle East supply disruptions and growing antiplatelet and cardiovascular sector demand globally.
Clopidogrel is a thienopyridine antiplatelet prodrug produced by multi-step synthesis from methyl 2-chlorophenylacetate through condensation with thieno[3,2-c]pyridine and asymmetric resolution to isolate the pharmacologically active S-enantiomer, supplied as the hydrogen sulfate bisulfate salt. As an inactive prodrug, clopidogrel requires hepatic bioactivation through two sequential CYP450 oxidation steps, principally by CYP2C19, to generate the active thiol metabolite that irreversibly alkylates the P2Y12 ADP receptor on the platelet surface, blocking ADP signalling and inhibiting platelet aggregation for the remaining platelet lifetime of approximately seven to ten days. The largest pull comes from dual antiplatelet therapy following percutaneous coronary intervention and coronary stent placement combined with aspirin for prevention of stent thrombosis and recurrent cardiac events. Secondary prevention in patients with prior myocardial infarction, ischaemic stroke, or peripheral arterial disease and acute coronary syndrome management add significant further demand. Atrial fibrillation antiplatelet therapy in patients unsuitable for anticoagulants adds consistent further demand. Thienopyridine synthesis intermediate costs, cardiology prescribing volumes, and regional API production capacity all feed into the price.
The balance of supply and demand for Clopidogrel through H2 2026 leans moderately firm. Thienopyridine synthesis intermediate costs firmed from Middle East chemical supply disruptions. Cardiovascular secondary prevention, coronary stent, and acute coronary syndrome demand are growing with expanding interventional cardiology capacity globally.
The main upside risk is synthesis intermediate cost increases alongside accelerating percutaneous coronary intervention volumes and DAPT prescribing. The main downside risk is prasugrel and ticagrelor prescribing preference shift and Chinese and Indian API surplus maintaining price pressure below the forecast range.
| Region | Price Forecast (USD/KG) | Key Driver |
| Global Average | 58.0 - 65.1 | Synthesis cost firming and cardiovascular/ACS/stent demand |
| United States | 62.2 - 69.3 | Steady secondary prevention and stent demand holds firm |
| China | 42.0 - 49.1 | Large API capacity keeps it the most affordable |
| Germany | 77.8 - 84.9 | High synthesis and energy costs keep it the most expensive |
| India | 59.8 - 66.9 | Growing antiplatelet and export demand holds a firm middle |
US Clopidogrel prices averaged USD 69.6/KG in Q2 2026, up 8.1% from USD 64.4/KG in Q1 2026. Firmer synthesis intermediate costs and recovering cardiovascular and coronary stent procurement drove consistent buying following the Q1 moderation.
Why did the price of Clopidogrel change in Q2 2026 in the United States?
Firmer thienopyridine synthesis intermediate costs raised the API production floor. Coronary stent DAPT, acute coronary syndrome, and secondary prevention atherothrombotic event procurement lifted buying. Peripheral arterial disease and atrial fibrillation antiplatelet demand provided support near USD 69.6/KG.
Chinese Clopidogrel prices averaged USD 48.2/KG in Q2 2026, up 8.1% from USD 44.6/KG in Q1 2026, the lowest among the tracked markets. Spring cardiovascular and antiplatelet export and domestic procurement lifted buying. Firmer domestic synthesis costs raised the floor despite large domestic API capacity.
Why did the price of Clopidogrel change in Q2 2026 in China?
Spring cardiovascular and coronary stent antiplatelet export and domestic procurement lifted buying. Firmer domestic thienopyridine synthesis costs raised the production floor. Large domestic API capacity kept China the most affordable source near USD 48.2/KG.
German Clopidogrel prices averaged USD 85.4/KG in Q2 2026, up 8.0% from USD 79.1/KG in Q1 2026, the highest among the tracked markets. Higher synthesis intermediate and energy costs elevated European production economics. Recovering cardiovascular secondary prevention and stent demand maintained buying.
Why did the price of Clopidogrel change in Q2 2026 in Germany?
Higher thienopyridine synthesis intermediate and energy costs elevated European production economics. Middle East supply disruptions added cost premiums. Recovering cardiovascular secondary prevention, coronary stent DAPT, and acute coronary syndrome procurement maintained buying near USD 85.4/KG.
Indian Clopidogrel prices averaged USD 66.5/KG in Q2 2026, up 7.9% from USD 61.6/KG in Q1 2026. Growing cardiovascular secondary prevention, coronary stent, and antiplatelet export and domestic demand supported buying. Firmer synthesis import costs raised the production floor.
Why did the price of Clopidogrel change in Q2 2026 in India?
Growing cardiovascular antiplatelet and coronary stent export and domestic procurement lifted buying. Firmer thienopyridine synthesis import costs raised the floor. Secondary prevention and essential medicine export demand provided additional support near USD 66.5/KG.
US prices averaged USD 64.4/KG in Q1 2026, easing about 1.0% from Q4 2025. Post-quarter cardiovascular and stent procurement moderation and soft synthesis costs eased the market before the Q2 spring procurement surge.
Why did the price of Clopidogrel change in Q1 2026 in the United States?
Post-quarter cardiovascular secondary prevention and stent DAPT procurement moderation reduced urgency. Soft thienopyridine synthesis costs eased the production floor. The market eased to USD 64.4/KG before the Q2 spring cardiovascular season surge.
Chinese prices averaged USD 44.6/KG in Q1 2026, easing about 0.9% from Q4 2025. Post-Lunar New Year cardiovascular and antiplatelet procurement moderation held the market near USD 44.6/KG.
Why did the price of Clopidogrel change in Q1 2026 in China?
Post-Lunar New Year cardiovascular and antiplatelet procurement moderation reduced urgency. Soft domestic synthesis costs eased the production floor. The market eased to USD 44.6/KG before the Q2 spring cardiovascular procurement surge.
German prices averaged USD 79.1/KG in Q1 2026, easing about 0.8% from Q4 2025. Post-quarter cardiovascular and stent procurement moderation and soft synthesis and energy costs eased the European market near USD 79.1/KG.
Why did the price of Clopidogrel change in Q1 2026 in Germany?
Post-quarter cardiovascular and coronary stent procurement moderation reduced urgency. Soft synthesis intermediate and energy costs eased the production floor. The market eased to USD 79.1/KG before the Q2 spring surge.
Indian prices averaged USD 61.6/KG in Q1 2026, easing about 1.0% from Q4 2025. Post-holiday cardiovascular and antiplatelet procurement moderation held the market near USD 61.6/KG.
Why did the price of Clopidogrel change in Q1 2026 in India?
Post-holiday cardiovascular and antiplatelet procurement moderation reduced urgency. Soft synthesis import costs eased the production floor. The market eased to USD 61.6/KG before the Q2 spring cardiovascular procurement surge.
Global Clopidogrel prices followed an alternating pattern, dipping in Q3 2025 and Q1 2026 on seasonal procurement moderation before recovering in Q4 2025 and surging in Q2 2026. The average eased from USD 55.0/KG in Q2 2025 to USD 54.45/KG in Q3, recovered to USD 55.54/KG in Q4, eased to USD 54.98/KG in Q1 2026, then surged to USD 59.40/KG in Q2 2026, a net gain of about 8.0% over the window. Thienopyridine synthesis cost cycles and cardiovascular secondary prevention, coronary stent, and acute coronary syndrome procurement drove the alternating pattern.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 59.40 | +8.0% | ↑ Rising |
| Q1 2026 | 54.98 | -1.0% | ↓ Falling |
| Q4 2025 | 55.54 | +2.0% | ↑ Rising |
| Q3 2025 | 54.45 | -1.0% | ↓ Falling |
| Q2 2025 | 55.0 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Clopidogrel prices were broadly stable through 2025 on consistent cardiovascular and coronary stent demand. The global average opened near USD 56.1/KG in Q1 2025 and closed at USD 55.54/KG in Q4, a marginal full-year decline of about 1.0%. Thienopyridine synthesis cost dynamics and cardiovascular prescribing volumes maintained stable to slightly softer conditions through the year.
US prices fell from about USD 66.1/KG in Q1 2025 to USD 65.0/KG by Q4, a decline of 1.7%. Stable cardiovascular and stent demand maintained conditions through the year.
Chinese prices fell from roughly USD 45.7/KG in Q1 2025 to USD 45.0/KG by Q4, a decline of 1.5%. Large domestic API capacity maintained the lowest level.
German prices fell from about USD 81.3/KG in Q1 2025 to USD 79.9/KG by Q4, a decline of 1.7%. Soft synthesis costs maintained moderate downward pressure through the year.
Indian prices fell from roughly USD 63.2/KG in Q1 2025 to USD 62.2/KG by Q4, a decline of 1.6%. Soft synthesis import costs maintained moderate downward pressure through the year.
Expert Market Research: Your Source for Real-Time Clopidogrel Price Intelligence
Expert Market Research tracks Clopidogrel prices continuously across every major producing and consuming region. The team traces causation through thienopyridine synthesis intermediate economics, cardiovascular secondary prevention and coronary stent procurement cycles, and regional API production capacity. Contact Expert Market Research today for Clopidogrel pricing data, bespoke market analysis, and strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Dual antiplatelet therapy following percutaneous coronary intervention and coronary stent placement combined with aspirin for prevention of stent thrombosis and recurrent cardiac events takes the largest share globally. Secondary prevention of atherothrombotic events in patients with prior myocardial infarction, ischaemic stroke, or peripheral arterial disease, and acute coronary syndrome management also consume significant volumes globally.
The Q2 2026 average was USD 69.6/KG in the United States, USD 48.2/KG in China, USD 85.4/KG in Germany, and USD 66.5/KG in India. Germany remains the highest-priced market.
The global average rose from USD 54.98/KG in Q1 to about USD 59.40/KG in Q2, a gain of around 8.0%. Spring cardiovascular and coronary stent procurement and firmer synthesis intermediate costs drove the H1 surge following the Q1 moderation.
Cardiovascular secondary prevention and coronary intervention procurement cycles create alternating quarterly buying patterns. Post-season moderation in Q1 and Q3 creates dips while spring cardiovascular and stent DAPT procurement surges drive upticks.
The global average is expected in the USD 58.0 to 65.1/KG range for H2 2026, with continued firming as synthesis costs stay elevated and cardiovascular, coronary stent, and ACS demand grows.
Germany sits highest on synthesis and energy costs, the United States and India hold a firm middle on cardiovascular and stent demand, and China prices lowest on large domestic API capacity.
This report is updated monthly. For real-time pricing intelligence, contact the Expert Market Research team directly.
Prices respond mainly to thienopyridine synthesis intermediate costs, coronary stent placement and cardiovascular prescribing cycles, and CYP2C19 pharmacogenomics testing adoption. Synthesis precursor prices and cardiology procedure volumes are key signals.
China and India hold the largest clopidogrel API synthesis capacity. Any thienopyridine synthesis intermediate cost shift ripples across markets within one to two quarters.
Buyers can use quarterly trends and forecasts to time cardiovascular and stent antiplatelet contracts around synthesis cost cycles, build cover when thienopyridine intermediate signals tighten, and monitor coronary intervention procedure volumes as demand signals.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.